USPTO serial 79290058
NOVO NORDISK
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 13, 2021
- Examiner
- EVANKO, PATRICIA MALESARDI
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with NOVO NORDISK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,793*
Plus Government fees of $2,275
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexander Reid
Alexander Reid White & Case LLP1221 Avenue of the AmericasTrademark DepartmentNew York, NY 10020Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations for use in industry; chemical additives for use in the manufacture of pharmaceuticals, cosmetics, hair lotions, disinfectants; chemical diagnostic reagents for industrial use, for non-medical and non-veterinary purposes; chemical preparations for use in the oil industry | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of diabetes and obesity; pharmaceutical preparations for haemostasis management and for the treatment of sickle cell disease; pharmaceutical preparations for the treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease; pharmaceutical preparations for hormone therapy and stem cells for medical purposes; drug delivery devices containing pharmaceutical preparations for haemostasis management, pharmaceutical preparations for the treatment of sickle cell disease, brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, pharmaceutical preparations for hormone therapy and stem cells for medical purposes; chemical preparations for use in medical devices, namely, drug delivery agents consisting of compounds that deliver a wide range of pharmaceuticals | ACTIVE | — |
| 009 | downloadable electronic publications, namely, leaflets, books, booklets, handouts, magazines, as well as medical, instructional and teaching material in the field of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; downloadable electronic publications featuring electronic reports containing results from clinical trials and studies in the field of prevention and treatment of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; downloadable software applications for use with mobile devices for monitoring and management of medical data related to diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; computer hardware and downloadable software, for use with medical injection devices for collecting, transmitting, and displaying medical data; downloadable medical software for the management of medical data related to diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; downloadable software as a medical device, namely, software used in connection with medical devices to manage treatment of haemostasis management and for the treatment of sickle cell disease, brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cells for medical purposes | ACTIVE | — |
| 010 | Medical and surgical apparatus and instruments, namely, hypodermic syringes and syringe pens; medical apparatus and instruments for reconstitution and injection of pharmaceutical preparations; medical apparatus and instruments, namely, injection devices for administration of pharmaceutical preparations, medical infusion pumps for delivering measured amounts of solutions into the bloodstream over time, infusion pump controllers, adhesive infusion devices for administering drugs; digitally connected medical devices for monitoring the dispensation of pharmaceutical preparations for use in connection with the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; medical and surgical apparatus and instruments, namely, injection devices for the administration of pharmaceutical preparations and the wireless transmission of medical data in connection with the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; medical devices, namely, automatic needle insertion devices, protection caps for hypodermic syringes and medical pens; needles for injections; cartridges and carpules for administration of pharmaceutical preparations | ACTIVE | — |
| 041 | Educational services, namely, organizing and conducting educational programmes, coaching and training services for patients and healthcare professionals related to management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; arranging and conducting of educational conferences, congresses, seminars, symposiums and workshops related to the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment | ACTIVE | — |
| 042 | Providing scientific research information in the field of diabetes, obesity, haemostasis management, treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; providing temporary use of online non-downloadable software featuring technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment | ACTIVE | — |
| 044 | Providing medical services via websites and mobile apps for the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; providing medical information and medical counselling featuring the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Novo Nordisk A/S
- Other trademarks owned by Novo Nordisk A/S
- Other trademarks owned by Novo Nordisk A/S
- Other trademarks owned by Novo Nordisk A/S
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NOVO NORDISK
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 2, 2026 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Aug 15, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 27, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 27, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 13, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 13, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 6, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 26, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 26, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 13, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 6, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 6, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 17, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 17, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 17, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 17, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 17, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 17, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 17, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 17, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 9, 2020 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Nov 18, 2020 | CRSN | CORRECTION SENT TO IB | — |
| Nov 11, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 11, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 10, 2020 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Sep 27, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 6, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 2, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 1, 2020 | CRCR | CORRECTION CREATED FOR IB | — |
| Jul 30, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 29, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 28, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 24, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 24, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 23, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |